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Background: Recent media reports have focussed on the large increase in items of 
antidepressant dispensed in England. We investigated this, focussing on SSRI. 
 
Aims: To examine the rate of initiation of SSRIs over time and changes over time in the 
duration of prescribing episodes. 
 
Method: We estimated initiation and duration of SSRI prescribing from 7,025,802 
individuals aged over 18 years and registered with a general practice that contributed data 
to The Health Improvement Network. 
 
Results: Rates of SSRI initiation increased from 1.03 per 100 person years in 1995 to 2.15 in 
2001, but remained stable from then to 2012. The median duration of prescribing episodes 
increased from 112 to 169 days for episodes starting in 1995 to 2010. 
 
Conclusions: Despite media reports describing the increasing rate of antidepressant 
prescribing, SSRI initiation rates have stabilised since 2001. However, our results suggest 
that individuals who take SSRIs are receiving treatment for longer. 
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Introduction 
 
Recent media reports have focussed on the large increase in prescriptions for 
antidepressants in the UK.1–3 The implication of some of these reports is that depression is 
on the rise, perhaps driven by the recent financial crisis.1 However, the number of 
antidepressants dispensed  in England each year has been steadily on the rise since at least 
as far back as 1991, with approximately 9 million items dispensed in 1991 rising to 50 million 
items dispensed in 2012.4 Selective serotonin reuptake inhibitors (SSRIs) accounted for more 
than 50% of the items dispensed with citalopram accounting for more than 13 million of the 
dispensed items in each year between 2011 and 2012.4 Nonetheless, the UK Psychiatric 
Morbidity Surveys have reported little overall change in the prevalence of common mental 
disorders such as depression and anxiety in England between 1993 and 2007.5 This has led 
to suggestions that the rise in items of antidepressants dispensed over time is instead due 
to an increase in the number of people taking them long term. 6 
 
In this study we aimed to explore this further, with a particular focus on prescribing of SSRIs 
between 1995 and 2012. Our specific aims were (1) to examine the rate of new SSRI 
prescribing over time and the socio demographic factors associated with new prescribing; 
(2) to examine changes over time in the total amount of time for which the people were 
prescribed SSRIs and (3) to examine changes over time in the duration for which people 
were prescribed the drug. 
 
Method 
 
Data source 
The data for this study come from The Health Improvement Network (THIN; 
http://csdmruk.cegedim.com/), a large UK primary care database. THIN contains the 
longitudinal health records of approximately 12 million patients who are registered with a 
general practice (family doctor), and is broadly representative of the UK population.7 In the 
UK 95% of the population is registered with a general practice and THIN contains records of 
all prescriptions issued there – most prescribing in the UK is carried out by a general 
practitioner even when the decision to start a drug is made by a hospital specialist. THIN 
also contains patient demographic information including Townsend score: this is a measure 
of deprivation based on census data for car ownership, owner-occupation, overcrowding 
and unemployment in a patient’s postcode and is categorised into quintiles. 
 
The scheme for THIN to obtain and provide anonymous patient data to researchers was 
approved by the National Health Service South-East Multicentre Research Ethics Committee 
(MREC) in 2002 and scientific approval for this study was obtained from CSD Medical 
Research's Scientific Review Committee in December 2014. 
 
Time period and study population 
We examined SSRI prescribing during the period from 1st January 1995 to 31st December 
2012. Individuals were included from the latest of their date of registration, the year at 
which they turned 18 years of age or the dates at which their practice reached the 
standards for acceptable computer use and mortality recording.8,9 Follow up ended when an 
individual left the practice or died.  
 
Selective serotonin reuptake inhibitors 
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SSRI prescriptions were identified by drug codes that were linked to the British National 
Formulary (BNF) codes in chapter 4.3.3 (Selective serotonin re-uptake inhibitors). In the UK, 
general practitioners (family doctors) use BNF as their guidance for prescribing 
(www.medicinescomplete.com/about/publications.htm). 
 
Outcomes of interest  
1) The rate of new SSRI prescriptions per 100 person years at risk. 
SSRI prescriptions were treated as being part of a single prescribing episode if they 
were within 365 days of each other. We considered prescribing episodes involving 
more than one prescription since it seems more plausible that individuals who return 
for a second prescription will have initiated treatment, whereas many individuals 
who receive only one prescription may never have initiated treatment.  
 
 
We excluded prescribing episodes with a first prescription before the start of follow 
up or less than 365 days after the individual registered with their practice since these 
individuals may have initiated an SSRI while registered with their previous practice. 
 
 
2) The amount of person time spent on SSRI prescriptions.  
This was defined as the total amount of time (in years) spent by all individuals in 
episodes of SSRI prescribing divided by the total follow-up time. 
 
For this outcome, SSRI prescriptions were treated as being part of a single episode if 
they were within 91 days of each other; episodes were considered to finish on the 
date of the final prescription. We chose the cut-off of 91 days because, while most 
individuals receiving repeat prescriptions were receiving monthly prescriptions, 
some individuals were receiving prescriptions every two months; the cut-off of 91 
days allowed these individuals to collect some prescriptions early or late without 
being considered to have discontinued. Again, we only considered prescribing 
episodes involving more than one prescription. 
 
3) The length of prescribing episodes. 
Prescriptions were counted as being in the same episode if they were within 91 days, 
while episodes were considered to finish on the date of the final prescription. As 
above, we only considered episodes involving more than one prescription; hence, 
episodes starting and ending on the same day were excluded. Likewise, we were not 
able to estimate duration of episodes starting within 91 days of an individual 
registering at the practice, since individuals may have initiated treatment before 
they joined the practice. We allowed at least two years of follow-up for all episodes, 
and therefore excluded new episodes starting in 2011 and 2012. 
 
 
Statistical analyses  
  
The rate of new SSRI prescriptions per 100 person years at risk was calculated as the 
number of individuals receiving their first SSRI prescription in a prescribing episode (see 
below) during a specified period divided by the total person years at risk. Time at ‘risk’ 
comprised the time to an individual’s first SSRI prescription, time between prescribing 
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episodes (excluding the 365 day period after the end of a prescribing episode where any 
prescriptions would be counted as part of the preceding episode), time to their end of 
follow-up after their final prescribing episode, or all time from the start to end of follow-up 
if they have no SSRI prescriptions.. We plotted the rate of new SSRI prescribing over time, 
both overall and by individual SSRIs. We then used Poisson regression to examine the 
relationship between SSRI initiation and gender, age and Townsend score quintile. Models 
were estimated separately for men and women to allow the relationships to differ by 
gender, and all models included a random effect to account for clustering by practice and 
robust variance estimates. Adjustment variables were age, Townsend quintile and year. 
Individuals with missing Townsend score (6.2%) were excluded from all Poisson regression 
analyses.  
 
Further, we estimated the proportion of the total episodes which constituted a single 
prescription over time and as a sensitivity analysis we included these in the overall 
estimates of initiation of SSRI.  
 
The amount of person time spent on SSRI prescriptions was estimated as the total amount 
of time (in years) spent by all individuals in episodes of SSRI prescribing divided by the total 
follow-up time and results were provided  as the number of person years on SSRIs per 100 
person years, which was then plotted over time. As an example, an individual initiating an 
SSRI at the start of January 2001 and receiving their final prescription at the end of June 
2002 would contribute one year of person time to the numerator for 2001 and 6 months of 
person time to the numerator for 2002; they would contribute person time to the 
denominator for every year during which they were under follow-up.  
 
We estimated the length of prescribing episodes as median, upper and lower quartiles of 
SSRI prescribing episode duration. These were plotted over time (focussing on the year that 
the prescribing episode started), and we also examined the relationship between duration 
of prescribing episode and gender, age, Townsend score quintile and the number of the 
prescribing episode.  
 
The data were analysed using Stata version 13.1. 
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Results 
 
We analysed data from 7,025,802 individuals registered at 584 general practices across the 
UK. The mean follow-up time was 6.3 years, while the total follow-up was 44,590,161 years. 
In total, 655,357 individuals initiated an SSRI during follow-up, with 78.9% initiating an SSRI 
prescribing episode only once, 16.4% initiating an SSRI twice, and 4.7% initiating an SSRI 
three or more times during follow-up. 
 
The rate of new SSRI prescribing increased from 1.03 per 100 person years in 1995 to 2.15 in 
2001 (Figure 1, top panel). After 2001, the initiation rate remained relatively stable 
thereafter. During the same period there were substantial changes in the rate of new 
prescribing for individual SSRIs (Figure 1, bottom panel). In 1995, the two most frequently 
initiated SSRIs were fluoxetine and paroxetine, whereas by 2012 citalopram and sertraline 
joined fluoxetine as the most frequently initiated drugs. The rate of new prescribing of 
paroxetine fell sharply from 0.61 per 100 person years in 2001 to 0.12 in 2004. Meanwhile, 
the rate of first citalopram prescribing increased steadily from 0.01 per 100 person years in 
1995 to 1.33 in 2010. 
 
[Figure 1 here] 
 
Sensitivity analysis investigating prescribing episodes that constituted just a single 
prescription resulted in a rate of new SSRI prescribing episodes of 0.54 per 100 person years 
in 1995, and 0.83 per 100 person years in 2003. In 2012 it was 0.75 per 100 person years. 
The proportion of all new SSRI episodes constituting of a single prescription has declined 
from 35% in 1995 to 27% in 2005 and since remained steady around this level (see 
supplementary material). Hence, including those with just a single prescription increased 
the overall estimates of SSRI initiation, but the time trends of new SSRI prescribing 
remained the same (see supplementary material).   
 
 
 
 
Women were more than twice as likely as men to initiate an SSRI during follow-up (adjusted 
rate ratio: 2.14, 95% CI: 2.13, 2.15). Age was also related to the rate of SSRI initiation, 
although this varied by gender (Table 1). For both men and women, the rate of new 
prescribing was lowest in the 60-79 years age band. For men, the rate of new SSRI 
prescribing was highest in those aged 80 years or over (adjusted rate ratio compared to 
those aged 18-39 years: 1.29, 95% CI: 1.25, 1.34). For women, the rate of new SSRI 
prescribing was highest in those aged 18-39 years – women in the 60-79 years age range 
were nearly half as likely to receive a first SSRI prescription as those in the 18-39 years age 
range (rate ratio: 0.55, 95% CI: 0.54, 0.57), while women aged 80 years or over were 0.68 
times as likely to initiate an SSRI (95% CI: 0.66, 0.70) compared to the 18-39 years reference 
group. Social deprivation (quintiles of the Townsend scores) was also related to the rate of 
new SSRI prescribing with the rates steadily increasing with increasing level of deprivation. 
Thus, men from the most deprived area (Townsend quintile 5) were 74% (95% CI 70% to 
78%) more likely to initiate SSRIs than men from the least deprived areas (Townsend 
quintile 1). The patterns were similar for women (Table 1).  
 
[Table 1 here] 
7 
 
 
While the rate of new SSRI prescribing has remained relatively stable over time since 2001, 
the same is not true for the amount of person time spent on SSRI prescriptions (Figure 2, 
top panel). This has risen sharply from 0.73 years of SSRI prescribing per 100 person years in 
1995 to 4.94 in 2012, with a rise every year. Similarly, there have been increases in the 
median duration of SSRI prescribing episodes over time (Figure 2, bottom panel): the 
median duration of an episode of prescribing went from 112 days for episodes starting in 
1995 to 169 days for episodes starting in 2010. Meanwhile, the 25th percentile of episode 
duration increased from 51 days to 70 days and the 75th percentile increased from 256 days 
to 440 days over the same period. 
 
[Figure 2 here] 
 
The median duration of an SSRI prescribing episode also varied according to the individual’s 
characteristics (Table 2). Episodes tended to be longer for women than for men – median 
episode length was 154 days (Inter Quartile Range (IQR) 66 to 375) for women compared to 
141 days (IQR 59 to 358) for men. Median duration of episode also varied by age – it was 
longest for those in the highest age group at 192 days (IQR 65 to 562) compared to 123 days 
(IQR 56 to 275) for those aged 18-39. Median duration of prescribing was also longer for 
those who had had more than one episode of SSRI prescribing: those on their third or higher 
episode of prescribing had a median episode length of 162 days (IQR 72 to 408) compared 
to 136 days (IQR 55 to 325) for those on their first episode. 
 
[Table 2 here] 
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Discussion 
 
Despite the reports in the media on the substantial increase in the rate of antidepressant 
prescribing, our results suggest there has been no similar continued increase in the rate of 
SSRI initiation over time. While the rate of SSRI initiation rose between 1995 and 2001, we 
found that the rate of new prescribing remained relatively stable between 2001 and 2012. 
Over the same period of 2001 to 2012, the number of antidepressant items dispensed in 
England rose from 24 million to 50 million, with citalopram, fluoxetine, sertraline and 
paroxetine accounting for more than half of the items dispensed in 2012.4  Other 
antidepressants commonly dispensed in 2012 included amitriptyline, often used for 
indications such as nerve pain and nocturnal enuresis (10.3 million dispensed items), 
venlafaxine (2.9 million dispensed items) and mirtazapine (5.3 million dispended items)4 .  
 
Our results suggest that for SSRIs the dramatic increase in dispensing does not appear to 
reflect a large increase in the number of people initiating SSRIs. Instead, it seems that 
individuals who take SSRI are each receiving more prescriptions and for a longer period of 
time. 
 
Similar increases in the number of antidepressant prescriptions have been seen in many 
other OECD countries between 2000 and 2011.10 The OECD report suggests four possible 
reasons for the increase in antidepressant consumption across all countries: 1) greater 
intensity and duration of treatment; 2) use for a broader set of indications such as milder 
forms of depression and generalised anxiety disorder; 3) greater social acceptability of 
antidepressants and willingness to seek treatment; and 4) increased insecurity related to 
the recent financial crisis. For the UK at least, only the first of these explanations is 
consistent with the findings of the present paper; the other three explanations would all 
result in an increase in the rate of SSRI initiation in the relevant time period that was not 
seen here. However, media coverage of the OECD report focussed on the other 
explanations, leading to claims that antidepressants are increasingly being 
overprescribed.11,12 This highlights the importance and need for more detailed analysis of 
individual level rather than aggregated  data. 
 
While there has been little change overall in the rate of SSRI initiation since 2001, there 
have been considerable changes in the patterns of prescribing for individual drugs. One of 
the most notable changes is the decline in the rate of new prescribing of paroxetine from 
2001 to 2003. A similar decline has been noted in the numbers of prescriptions for 
paroxetine issued by general practitioners in England; this decline has been linked to a US 
Food and Drug Administration regulatory communication about withdrawal symptoms 
associated with paroxetine, as well as three UK Panorama television programs suggesting 
links between paroxetine and suicidal behaviour.13 However, the decline in initiation of 
paroxetine also coincides with when the drug ceased to be actively marketed around that 
time. In contrast, we found that citalopram and, more recently, sertraline have been 
increasingly initiated, in line with the findings by the Health and Social Care Information 
Centre.4 The reasons for these changes may be related to a reduction in cost and sertraline 
being recommended specifically in NICE Depression guidance as suitable for elderly 
individuals with cardiovascular disease.14 
 
Our primary analyses focused on initiation of SSRIs involving treatment episodes including at 
least two prescriptions as it seems more plausible that individuals who return for a second 
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prescription may be more likely to have initiated treatment than those who received just 
one prescription. However, it should be noted that a large number of individuals received a 
single SSRI prescription, since 2005 this has constituted approximately 25-27% of all new 
prescribing episodes.  
 
The total amount of person time spent on SSRI prescriptions has been rising steadily since 
1995. This mirrors the increase in issued prescriptions that has been seen in England over 
the same period.4 As we have seen, this rise in the amount of person time being spent on 
SSRIs does not appear to be linked to an increase in the number of people being started on 
SSRIs, at least from 2001 onward. Instead, this rise seems to be at least partially explained 
by the increase in the duration of prescribing episodes observed over this period. This 
finding is consistent with an earlier study by Moore et al. that examined prescribing data for 
antidepressants up to 2005:6 the authors concluded that the rise in antidepressant 
prescribing was down to a small increase in the number of people on long term treatment. 
The present paper demonstrates that there has been a rise in the average duration of 
treatment beyond 2005 up to 2012. It also highlights the fact that the increase in duration is 
seen not only among those on long term treatment, but also among those in the middle and 
lower end of the episode duration distribution: this is shown by the increases in duration for 
the median and 25th percentile shown in the bottom panel of Figure 2.  
 
The rate of SSRI initiation differed by demographic characteristics. In general, the initiation 
rate was higher in women than in men. This is consistent with the higher prevalence of 
common mental disorders that has been reported among women.5 Also notable was the 
higher rate of new prescribing among men aged 80 or more; this contradicts the findings of 
the 2007 Psychiatric Morbidity Survey in England, which reported the lowest prevalence of 
depressive episodes and common mental disorders for men aged 75 or over. Similarly, the 
Psychiatric Morbidity Survey reports that the prevalence of common mental disorders in 
women is lowest among those aged 75 or over. However, we found that the SSRI initiation 
rate was higher among those aged 80 or over than in those aged 60 to 79 years. Since the 
higher rate of new prescribing does not seem to reflect a higher prevalence of depression in 
these older age groups, further work is needed to understand the high levels of prescribing 
in these groups. This may reflect increased willingness of doctors to prescribe SSRIs to older 
individuals or a preference for drug treatment in comparison to other treatments that is 
specific for this age group. It may also reflect increased prescribing for off-label indications 
(e.g. neuropathic pain or fibromyalgia) in the older population. Alternatively, it is possible 
that the structured measurement instrument used to detect common mental disorders in 
the Psychiatric Morbidity Survey (the Clinical Interview Schedule-Revised) underestimates 
the prevalence of mental disorders in older individuals. 
 
The rate of SSRI initiation was also found to vary by Townsend quintile: for both men and 
women, those living in areas associated with the highest level of deprivation had a higher 
rate of new SSRI prescribing than those from the less deprived areas. This is consistent with 
the finding that those with the lowest household income have the highest prevalence of 
depressive episodes and other common mental disorders.5 
 
Length of prescribing also varied by demographic characteristics: it was shortest for males 
and for those aged 18 to 39 years. Furthermore, duration of prescribing was linked to how 
many episodes of prescribing an individual had experienced: those on their third or higher 
episode had a longer median duration than those on their first episode. This difference is 
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consistent with the 2009 treatment recommendation from the National Institute for Health 
and Care Excellence (NICE) that antidepressants should be continued for a minimum of 6 
months after remission, but that those with two or more episodes in the recent past should 
continue treatment for at least 2 years.14 However, the median length of episode for those 
on their third or higher episode was only 162 days, indicating that most of those in this 
group were prescribed SSRIs for considerably less than two years. 
 
Our study has some limitations. Since we used prescription data, we do not know if 
individuals were actually taking their prescribed medication. To handle this, we only 
considered prescribing episodes consisting of two or more prescriptions with the 
assumption that if these individuals came back for a repeat prescription it is more likely that 
they had taken the medication from the previous prescription. Similarly, we do not know 
when individuals stopped taking the medicine at the end of a prescribing episode; therefore, 
we simply counted the date of the individual’s last prescription as the end of the prescribing 
episode. This will consistently underestimate the duration of prescribing episodes, however 
since this underestimation is consistent it should not impact the relative comparisons made 
at different time points within our data. Likewise, it is possible that individuals may have 
been prescribed different dosages. In an ideal situation we would examine standardised 
prescribing volumes as Average Daily Quantities (ADQs). However, primary care data 
often lack detailed information on dose and therefore we were unable to perform such 
analysis. 
 
It is possible that SSRI prescriptions may be initiated by a psychiatrist, and so some 
individuals’ first prescriptions may not be captured in our data. However, even in this case 
repeat prescriptions in the UK are generally issued by the general practitioner and so these 
would be represented in our data, even though we may have underestimated the length of 
the prescribing episode. Additionally, we are unable to tell whether individuals had a 
previous episode of SSRI prescribing prior to joining their current general practice. 
Therefore, we may have underestimated some individuals’ number of episodes of SSRI 
prescribing.  
 
In this study the focus was on prescribing of SSRI, which are by far the most commonly used 
antidepressants. However, it is possible that the prescribing patterns differs for treatments 
such as amitriptyline, venlafaxine and mirtazapine and further research of the prescribing 
patterns of these medications are warranted.  
 
Initiation of SSRI prescribing in general practice has remained relatively constant from 2001 
to 2012, even though there has been a steady increase in the amount of person time spent 
on these drugs over this period. This is partially explained by an increase in the average 
duration of prescribing episodes over this period. While there has been considerable media 
attention on the rise in the number of antidepressant prescriptions issued, this does not 
seem to reflect the real picture of SSRI usage. Despite the findings of Moore et al, there 
remains a belief that antidepressants are being increasingly overprescribed for mild 
depression or other indications. While reporting of such theories in popular media may 
prove useful in ensuring that general practitioners and patients carefully consider whether 
antidepressants are suitable, it may also result in a reluctance to use antidepressants when 
they are actually appropriate. 
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This study demonstrates that, contrary to what has been widely suggested by the media, 
there has been no recent increase in SSRI initiation rates. The duration of treatment has 
increased congruent with current guidelines however it still falls short of NICE 
recommendations. It is unclear why general practitioners registered an increased rate of 
prescribing in older people. It may be related to lack of access to alternative treatments 
for depression such as CBT and other forms of talking therapies; further research is 
required to gain a better understanding of this phenomenon.         
 
 
 
Authors’ degrees, affiliations and full addresses 
Rachel L McCrea, PhD1 
Cormac J Sammon, PhD1 
Irwin Nazareth, PhD, FRCGP1 
Irene Petersen, PhD 1, 2 
 
1 Department of Primary Care and Population Health, University College London, London, 
United Kingdom, NW3 2PF. 
2 Department of Clinical Epidemiology, Aarhus University, Denmark, 8200 Aarhus.  
 
Author contributions 
Conception and design: RM IP. Analysis and interpretation of data: RM CS IN IP. Drafting the 
article: RM. Revising the article critically for important intellectual content: RM CS IN IP. 
Final approval of the version to be published: RM CS IN IP. 
 
References 
 
1  Batty D. Antidepressant use in England soars | Society | The Guardian. 2011. 
(http://www.theguardian.com/society/2011/dec/30/antidepressant-use-england-soars). 
2  Donnelly L. ‘Staggering’ rise in prescribing of antidepressants - Telegraph. 2014. 
(http://www.telegraph.co.uk/health/healthnews/10957417/Staggering-rise-in-
prescribing-of-antidepressants.html). 
3  Easton M. BBC News - Is England a nation on anti-depressants? 2013. 
(http://www.bbc.co.uk/news/uk-23553897). 
4  Health and Social Care Information Centre. Statins, antidepressants, diabetes prescribing 
items and NIC 1991 to 2013. 2013. (http://www.hscic.gov.uk/media/14818/statins-
antidepressants-diabetes-prescribing-items-and-NIC-1991-to-
2013/xls/Statins_AntiDep_Diabetes_1991_to_2013.xlsx). 
5  National Centre for Social Research. Adult Psychiatric Morbidity in England, 2007: Results 
of a Household Survey. 2009. 
6  Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in 
antidepressant prescribing: a descriptive study using the General Practice Research 
Database. BMJ 2009; 339: b3999–b3999. 
12 
 
7  Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement 
Network (THIN) database: demographics, chronic disease prevalence and mortality rates. 
Inform Prim Care 2011; 19: 251–5. 
8  Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in 
primary care research databases. Pharmacoepidemiol Drug Saf 2013; 22: 64–9. 
9  Maguire A, Blak BT, Thompson M. The importance of defining periods of complete 
mortality reporting for research using automated data from primary care. 
Pharmacoepidemiol Drug Saf 2009; 18: 76–83. 
10 OECD. Health at a Glance 2013: OECD Indicators. 2013. 
(http://dx.doi.org/10.1787/health_glance-2013-en). 
11 Martin D. Pill-popping Britain: UK takes more anti-depressants than almost all our EU 
neighbours. Mail Online. 2013. (http://www.dailymail.co.uk/news/article-2511186/Pill-
popping-Britain-UK-takes-anti-depressants-Europe.html). 
12 Boseley S, Chalabi M, Rice-Oxley M. Antidepressant use on the rise in rich countries, 
OECD finds. the Guardian. 2013. 
(http://www.theguardian.com/society/2013/nov/20/antidepressant-use-rise-world-
oecd). 
13 Martin RM, May M, Gunnell D. Did intense adverse media publicity impact on prescribing 
of paroxetine and the notification of suspected adverse drug reactions? Analysis of 
routine databases, 2001-2004. Br J Clin Pharmacol 2006; 61: 224–8. 
14 National Institute for Health and Clinical Excellence (NICE). Depression in adults: the 
treatment and management of depression in adults. NICE, 2009 
(http://guidance.nice.org.uk/cg90). 
 
 
 
  
13 
 
Table 1: Initiation rates and rate ratios for first prescription of an SSRI by age, 
Townsend quintile and year, stratified by gender 
 Initiation 
rate per 
100 PYAR 
RR 
unadjusted 
(95% CI) RR 
adjusted 
(95% CI) 
For men: 1.29     
Age      
   18-39 1.25 1 - 1 - 
   40-59 1.43 1.14 (1.12, 1.16) 1.16 (1.14, 1.18) 
   60-79 1.06 0.84 (0.82, 0.86) 0.85 (0.83, 0.87) 
   80 or over 1.63 1.30 (1.26, 1.34) 1.29 (1.25,1.34) 
Townsend quintile      
   1 (least deprived) 1.05 1 - 1 - 
   2 1.16 1.11 (1.09, 1.13) 1.11 (1.09, 1.13) 
   3 1.29 1.26 (1.23, 1.28) 1.26 (1.23, 1.28) 
   4 1.49 1.47 (1.44, 1.50) 1.48 (1.45, 1.50) 
   5 (most deprived) 1.75 1.74 (1.69, 1.78) 1.74 (1.70, 1.78) 
Year      
   1995-1997 0.81 1 - 1 - 
   1998-2000 1.14 1.45 (1.38, 1.52) 1.45 (1.38, 1.52) 
   2001-2003 1.32 1.67 (1.59, 1.76) 1.67 (1.58, 1.76) 
   2004-2006 1.22 1.54 (1.46, 1.62) 1.53 (1.45, 1.62) 
   2007-2009 1.31 1.65 (1.56, 1.75) 1.65 (1.56, 1.74) 
   2010-2012 1.48 1.88 (1.78, 1.99) 1.87 (1.77, 1.98) 
      
For women: 2.71     
Age      
   18-39 3.17 1 - 1 - 
   40-59 3.00 0.93 (0.92, 0.95) 0.96 (0.94, 0.97) 
   60-79 1.76 0.55 (0.53, 0.56) 0.55 (0.54, 0.57) 
   80 or over 2.20 0.69 (0.67, 0.71) 0.68 (0.66, 0.70) 
Townsend quintile      
   1 (least deprived) 2.26 1 - 1 - 
   2 2.46 1.10 (1.09, 1.12) 1.11 (1.09, 1.12) 
   3 2.74 1.26 (1.24, 1.28) 1.26 (1.24, 1.27) 
   4 3.13 1.45 (1.43, 1.48) 1.45 (1.43, 1.48) 
   5 (most deprived) 3.53 1.64 (1.60, 1.67) 1.64 (1.60, 1.67) 
Year      
   1995-1997 1.76 1 - 1 - 
   1998-2000 2.47 1.43 (1.37, 1.49) 1.43 (1.37, 1.50) 
   2001-2003 2.85 1.63 (1.55, 1.71) 1.64 (1.56, 1.72) 
   2004-2006 2.61 1.49 (1.41, 1.56) 1.49 (1.42, 1.57) 
   2007-2009 2.74 1.56 (1.49, 1.64) 1.58 (1.50, 1.66) 
   2010-2012 2.98 1.71 (1.62, 1.80) 1.73 (1.64, 1.82) 
Abbreviations: PYAR, person years at risk; RR, rate ratio. 
All models include a random effect for practice. Individuals with missing Townsend score 
(6.24%) are excluded from all analyses in this table. 
Variables adjusted for: age, Townsend quintile, year 
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Table 2: Median duration of prescribing episode in days by gender, age, 
Townsend score quintile and the number of the episode 
 Median 
(days) 
25th percentile 75th percentile 
Gender    
   Male 141 59 358 
   Female 154 66 375 
Age at episode start    
   18-39 123 56 275 
   40-59 166 71 407 
   60-79 188 71 532 
   80 or over 192 65 562 
Townsend quintile    
   1 (least deprived) 160 69 377 
   2 158 68 385 
   3 150 63 371 
   4 143 60 362 
   5 (most deprived) 139 58 363 
Episode number    
   First 136 55 325 
   Second 156 65 392 
   Third or higher 162 72 408 
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Figure 1: Top panel - overall rate of new SSRI prescribing. Bottom panel - rate of new SSRI prescribing by drug. 
Fluvoxamine has been omitted from this chart because the rate of new prescribing was so low (0.01 per 100 person 
years in 1995, and falling during the rest of the study period).   
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Figure 2: Top panel - total amount of time spent on SSRI prescriptions over time. Bottom panel - duration of prescribing 
episodes over time. 
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Supplementary material  
 
Figure A overall rates of initiation of SSRI. The upper line includes all new SSRI prescriptions. 
The lower line includes data from the primary analysis (i.e. excluded those who received just 
one prescription).  
18 
 
 
 
 
Figure B: The proportion of all new SSRI episodes constituting a single prescription 
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